123 related articles for article (PubMed ID: 2383173)
1. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.
Reile H; Spruss T; Müller R; Gust R; Bernhardt G; Schönenberger H; Engel J
Arch Pharm (Weinheim); 1990 May; 323(5):301-6. PubMed ID: 2383173
[TBL] [Abstract][Full Text] [Related]
2. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
[TBL] [Abstract][Full Text] [Related]
3. Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
Spruss T; Gust R; Müller R; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1990 Feb; 323(2):99-102. PubMed ID: 2334275
[TBL] [Abstract][Full Text] [Related]
4. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235
[TBL] [Abstract][Full Text] [Related]
5. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell line.
Reile H; Müller R; Gust R; Laske R; Krischke W; Bernhardt G; Spruss T; Jennerwein M; Engel J; Seeber S
Arch Pharm (Weinheim); 1990 Mar; 323(3):133-40. PubMed ID: 2344259
[TBL] [Abstract][Full Text] [Related]
6. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
[TBL] [Abstract][Full Text] [Related]
7. Platinum and palladium complexes containing ethylenediamine derivatives as carrier ligands and their antitumor activity.
Lee K; Tashiro T; Noji M
Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):702-3. PubMed ID: 8004720
[TBL] [Abstract][Full Text] [Related]
8. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
[TBL] [Abstract][Full Text] [Related]
9. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
Gust R; Faderl M; Schönenberger H
J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
[TBL] [Abstract][Full Text] [Related]
10. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
[TBL] [Abstract][Full Text] [Related]
11. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
12. Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes.
Gust R; Schönenberger H
Arch Pharm (Weinheim); 1993 Jul; 326(7):405-13. PubMed ID: 8357303
[TBL] [Abstract][Full Text] [Related]
13. Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.
vom Orde HD; Reile H; Müller R; Gust R; Bernhardt G; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
J Cancer Res Clin Oncol; 1990; 116(5):434-8. PubMed ID: 2229132
[TBL] [Abstract][Full Text] [Related]
14. Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity.
Gust R; Bernhardt G; Spruss T; Krauser R; Koch M; Schönenberger H; Bauer KH; Schertl S; Lu Z
Arch Pharm (Weinheim); 1995 Sep; 328(9):645-53. PubMed ID: 7487421
[TBL] [Abstract][Full Text] [Related]
15. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma.
Gust R
Arch Pharm (Weinheim); 1994 Jan; 327(1):49-54. PubMed ID: 8117188
[TBL] [Abstract][Full Text] [Related]
16. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2004 Jun; 337(6):335-48. PubMed ID: 15188223
[TBL] [Abstract][Full Text] [Related]
17. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity.
Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2004 Jun; 337(6):349-59. PubMed ID: 15188224
[TBL] [Abstract][Full Text] [Related]
18. Effect of N,N'-diethyl-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines on the 7,12-dimethylbenz[a]anthracene-induced mammary carcinoma of the rat.
von Angerer E
J Med Chem; 1982 Nov; 25(11):1374-7. PubMed ID: 6815325
[TBL] [Abstract][Full Text] [Related]
19. N,N'-Dialkyl-1,2-bis(hydroxyphenyl)ethylenediamines and N,N-dialkyl-4,5-bis(4-hydroxyphenyl)imidazolidines: syntheses and evaluation of their mammary tumor inhibiting activity.
von Angerer E; Egginger G; Kranzfelder G; Bernhauer H; Schönenberger H
J Med Chem; 1982 Jul; 25(7):832-7. PubMed ID: 6809943
[TBL] [Abstract][Full Text] [Related]
20. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
